Insmed Inc., a global biopharmaceutical company, has appointed Sara Bonstein as chief financial officer, responsible for leading the company’s global financial operations, including financial planning and analysis, investor relations, accounting, tax and treasury. She will also serve as a member of Insmed’s Executive Committee.

“Sara is an exciting addition to our management team as we continue our efforts to bring ARIKAYCE® to patients around the world,” said Will Lewis, Chairman and Chief Executive Officer of Insmed. “In addition to her experience as a public company CFO, she also brings expertise in process improvement and a unique perspective from having served at both large and smaller life sciences companies. Sara is an exceptional talent and her extensive financial and leadership experience will be important as we continue to transform into a global, commercial organization, and we welcome her to the team.”

Ms. Bonstein joins Insmed with more than 15 years of financial and operational experience in the life sciences industry, most recently serving as chief financial officer and chief operating officer of OncoSec Medical Inc. Prior to joining OncoSec, Ms. Bonstein served as the chief financial officer, secretary, treasurer and executive vice president at Advaxis, Inc. Before Advaxis, Ms. Bonstein was a Six Sigma Champion & Black Belt at Eli Lilly & Co. and held key finance positions at ImClone Systems and Johnson & Johnson. 

“I am excited to be joining Insmed in the early phase of its international commercial expansion and its ambition to bring this success to other product development opportunities aligns with my background. I look forward to leading Insmed’s financial operations and joining the executive team,” commented Ms. Bonstein. “I am confident my past experience and industry expertise will serve the Company well and further its goal to transform the lives of patients with serious and rare diseases.”